maklogo
Market Research Report

Global Neurodegenerative Disease Drug Market Insights, Size, and Forecast By Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Dopamine Agonists, Monoclonal Antibodies, Antioxidants), By Disease Type (Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis), By End User (Hospitals, Specialty Clinics, Homecare Settings), By Route of Administration (Oral, Injectable, Transdermal, Intranasal), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035

Report ID:80469
Published Date:Jan 2026
No. of Pages:209
Base Year for Estimate:2025
Format:
Customize Report

Key Market Insights

Global Neurodegenerative Disease Drug Market is projected to grow from USD 58.4 Billion in 2025 to USD 115.2 Billion by 2035, reflecting a compound annual growth rate of 8.6% from 2026 through 2035. The market encompasses pharmaceutical interventions aimed at slowing disease progression, managing symptoms, or potentially reversing the effects of neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS). This robust growth is primarily driven by an aging global population, which significantly increases the prevalence of these age related disorders. Advances in scientific understanding of disease pathology are also fueling the development of novel therapeutic approaches. Furthermore, rising healthcare expenditure in developed and emerging economies, coupled with improved diagnostic capabilities, contributes to higher treatment rates and market expansion. The market is segmented by Disease Type, Drug Class, Route of Administration, and End User, with Alzheimer's Disease currently holding the largest share, underscoring the substantial unmet medical need and ongoing research efforts in this area.

Global Neurodegenerative Disease Drug Market Value (USD Billion) Analysis, 2025-2035

maklogo
8.6%
CAGR from
2025 - 2035
Source:
www.makdatainsights.com

Key market trends include a strong shift towards disease modifying therapies, moving beyond purely symptomatic treatments. This paradigm shift is evident in the burgeoning pipeline of biologics and gene therapies. Another important trend is the increasing adoption of personalized medicine approaches, leveraging biomarker identification for targeted therapies and more effective patient stratification. However, the market faces significant restraints, including the high cost associated with drug development and clinical trials for neurodegenerative diseases, which often have long durations and complex endpoints. Regulatory hurdles and the significant failure rate of drugs in late stage clinical trials also pose challenges. Despite these hurdles, substantial opportunities exist, particularly in the development of combination therapies, leveraging synergistic effects of different drug classes, and exploring repurposing existing drugs for new neurodegenerative indications.

North America is currently the dominant region in the global neurodegenerative disease drug market due to its advanced healthcare infrastructure, significant R&D investments, and favorable reimbursement policies. The presence of numerous key players and a high awareness of neurodegenerative conditions further solidify its leading position. Asia Pacific, however, is projected to be the fastest growing region, driven by its large and aging population, improving economic conditions, increasing healthcare access, and a growing emphasis on medical research and development. Key players like Eli Lilly, Roche, AbbVie, Biogen, Pfizer, Sanofi, Amgen, Teva Pharmaceuticals, Celgene, and Takeda are actively pursuing strategies such as strategic collaborations, mergers and acquisitions, and extensive R&D investments to expand their product portfolios and geographical reach. These companies are focused on bringing innovative therapies to market, often through partnerships with academic institutions and biotech firms, to address the profound unmet needs of patients suffering from these debilitating diseases.

Quick Stats

  • Market Size (2025):

    USD 58.4 Billion

  • Projected Market Size (2035):

    USD 115.2 Billion

  • Leading Segment:

    Alzheimer's Disease (42.5% Share)

  • Dominant Region (2025):

    North America (41.2% Share)

  • CAGR (2026-2035):

    8.6%

What is Neurodegenerative Disease Drug?

Neurodegenerative disease drugs target progressive loss of neuron structure and function, leading to conditions like Alzheimer's or Parkinson's. These medications aim to slow disease progression, alleviate symptoms, or, ideally, halt or reverse neuronal damage. They encompass various mechanisms, including amyloid or tau protein modulation, neuroinflammation reduction, neurotransmitter replacement, and neuroprotection strategies. The ultimate goal is to preserve cognitive function, motor control, and quality of life for patients. Development is complex due to brain's intricate nature and the slow, insidious onset of these diseases, making early detection and effective intervention critical for better patient outcomes.

What are the Trends in Global Neurodegenerative Disease Drug Market

  • Precision Medicine Navigating Neurodegeneration

  • AI Powered Drug Discovery Accelerating Treatments

  • Biomarker Driven Therapeutics Revolutionizing Diagnostics

  • Gene Therapy Innovations Expanding Treatment Horizons

  • Combination Therapies Redefining Patient Outcomes

Precision Medicine Navigating Neurodegeneration

Precision Medicine Navigating Neurodegeneration signifies a transformative shift in treating conditions like Alzheimer's and Parkinson's. Historically, neurodegenerative drug development relied on broad symptomatic approaches. Now, the focus is on understanding individual patient’s unique genetic makeup, molecular pathways, and disease progression profiles. This trend leverages advanced diagnostics, including biomarkers and genetic sequencing, to identify specific patient subgroups. Therapies are then tailored, targeting precise molecular mechanisms or pathological pathways unique to those subgroups. This personalized strategy promises more effective treatments with fewer side effects by matching the right drug to the right patient. It accelerates drug discovery and development by enabling more focused clinical trials and reducing the failure rate of non specific treatments, ultimately enhancing therapeutic outcomes for complex neurodegenerative disorders.

AI Powered Drug Discovery Accelerating Treatments

AI driven drug discovery is rapidly transforming the global neurodegenerative disease drug market. This trend reflects the application of sophisticated algorithms and machine learning to accelerate every stage of treatment development. Researchers are leveraging AI to analyze vast biological datasets identify novel drug targets and even design new molecular entities with unprecedented speed and precision.

This acceleration significantly shortens the time from initial research to clinical trials for conditions like Alzheimer's and Parkinson's. AI predicts drug efficacy and potential side effects much earlier optimizing compound selection and reducing costly failures. It also personalizes treatments by identifying patient subgroups likely to respond best to specific therapies leading to more effective and targeted interventions. This technological leap is pushing the boundaries of what is possible in developing urgently needed treatments.

What are the Key Drivers Shaping the Global Neurodegenerative Disease Drug Market

  • Rising Prevalence of Neurodegenerative Diseases

  • Advancements in Disease-Modifying Therapies and Diagnostics

  • Increased R&D Investment and Pharmaceutical Innovation

  • Growing Geriatric Population and Healthcare Spending

  • Supportive Regulatory Environment and Expedited Drug Approvals

Rising Prevalence of Neurodegenerative Diseases

The increasing occurrence of neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis is a primary driver of the global neurodegenerative disease drug market. As the world's population ages, the risk of developing these debilitating conditions significantly rises. This demographic shift leads to a larger patient pool requiring effective treatments to manage symptoms, slow disease progression, and improve quality of life. Pharmaceutical companies are intensifying research and development efforts to address this growing medical need, fostering innovation in drug discovery. The rising prevalence directly translates into higher demand for both existing and novel therapies, propelling market expansion as healthcare systems seek solutions for an ever increasing number of diagnosed individuals. This escalating burden necessitates continuous advancements in therapeutic options.

Advancements in Disease-Modifying Therapies and Diagnostics

Advancements in disease modifying therapies and diagnostics are profoundly reshaping the neurodegenerative disease landscape. New biologic drugs and small molecules are emerging that target specific pathological pathways implicated in diseases like Alzheimer’s Parkinson’s and Huntington’s. These therapies aim to slow or halt disease progression rather than merely managing symptoms representing a significant paradigm shift. Simultaneously diagnostic innovations including advanced imaging techniques and novel biomarkers enable earlier and more accurate disease detection. This allows for timely intervention potentially maximizing the efficacy of disease modifying treatments. Improved diagnostics also facilitate patient stratification for clinical trials leading to more targeted drug development. The synergy between these therapeutic and diagnostic breakthroughs is expanding treatable patient populations and driving substantial growth in the neurodegenerative disease drug market.

Increased R&D Investment and Pharmaceutical Innovation

Heightened research and development spending is a crucial impetus for advancements in the global neurodegenerative disease drug market. Pharmaceutical companies are allocating substantial resources to explore novel therapeutic targets and develop innovative treatments for conditions like Alzheimer's, Parkinson's, and Huntington's diseases. This increased investment fuels groundbreaking scientific discoveries, leading to a deeper understanding of disease mechanisms and the identification of promising new drug candidates. It supports the costly and lengthy processes of drug discovery, preclinical testing, and clinical trials. Furthermore, enhanced R&D enables the development of more effective, targeted, and disease modifying therapies, addressing significant unmet medical needs. This commitment to innovation is pivotal in bringing transformative medications to patients worldwide, driving growth in the market.

Global Neurodegenerative Disease Drug Market Restraints

High R&D Costs and Clinical Trial Failures

Developing new drugs for neurodegenerative diseases is immensely expensive. Research and development demands significant financial investment over many years, starting from basic scientific discovery through preclinical testing and multiple phases of human clinical trials. The complexity of the brain and the chronic nature of these diseases make drug development particularly challenging. Many promising candidates fail to demonstrate efficacy or safety in clinical trials, even after substantial investment. This high attrition rate means that only a small fraction of potential treatments ever reach the market. Pharmaceutical companies face substantial financial risk and long timelines, often spanning a decade or more, with no guarantee of success. This necessitates significant capital, which acts as a major barrier to innovation and limits the number of companies willing to undertake such high-stakes endeavors.

Stringent Regulatory Approval Processes and Market Access Challenges

Developing drugs for neurodegenerative diseases faces significant hurdles due to stringent regulatory approval processes. These diseases, often complex and progressive, require extensive clinical trials to demonstrate efficacy and safety. Regulatory bodies demand rigorous evidence of a drug's ability to slow or stop disease progression, improve patient quality of life, and possess an acceptable risk profile. This translates into prolonged development timelines and substantial financial investment for pharmaceutical companies. Furthermore, gaining market access in diverse global regions presents unique challenges. Each country or region has its own specific regulatory requirements, reimbursement policies, and pricing negotiations. Navigating these varied landscapes requires significant resources and strategic planning, potentially delaying patient access to crucial treatments and limiting a drug's global market reach.

Global Neurodegenerative Disease Drug Market Opportunities

Pioneering Disease-Modifying Therapies for Pre-Symptomatic Neurodegenerative Disorders

The global neurodegenerative disease drug market offers an unparalleled opportunity in pioneering disease modifying therapies specifically for pre symptomatic stages. Current treatments primarily alleviate symptoms, providing little impact on the underlying progression of debilitating disorders like Alzheimer’s or Parkinson’s. This represents a critical unmet need.

The opportunity lies in developing treatments that intervene before significant neuronal damage or clinical symptoms manifest. Imagine identifying individuals at genetic risk or with early biomarkers and deploying therapies decades before cognitive decline or motor impairment. Such early intervention holds the unprecedented potential to prevent disease onset altogether or substantially delay its devastating impact. This paradigm shift from reactive symptom management to proactive disease interception would transform patient outcomes, significantly reduce the immense global healthcare burden, and profoundly improve quality of life for millions. This new frontier targets an immense, largely untapped patient population, promising a highly valuable and transformative segment within the expansive neurodegenerative therapeutic landscape.

Expanding Genetic and Cell-Based Therapeutic Modalities for Neurodegenerative Diseases

The neurodegenerative disease drug market presents a significant opportunity in expanding genetic and cell based therapeutic modalities. Current treatments largely manage symptoms, leaving a vast unmet need for therapies that address underlying disease mechanisms or halt progression. Genetic therapies, including gene editing and antisense oligonucleotides, offer the unprecedented potential to correct causative genetic defects or modulate protein expression at the molecular level. Simultaneously, cell based therapies, such as stem cell transplantation, provide avenues for neuronal replacement, neuroprotection, and inflammation modulation. These advanced modalities represent a paradigm shift from traditional pharmacotherapy toward precision medicine and regenerative approaches. As scientific understanding of neurodegenerative pathways deepens, and technological capabilities in gene delivery and cell engineering mature, these innovative treatments are poised to deliver disease modifying or potentially curative outcomes. This expansion creates substantial growth for pharmaceutical and biotech companies developing these groundbreaking solutions, offering transformative hope for millions of patients globally and reshaping the future treatment landscape.

Global Neurodegenerative Disease Drug Market Segmentation Analysis

Key Market Segments

By Disease Type

  • •Alzheimer's Disease
  • •Parkinson's Disease
  • •Huntington's Disease
  • •Amyotrophic Lateral Sclerosis
  • •Multiple Sclerosis

By Drug Class

  • •Cholinesterase Inhibitors
  • •NMDA Receptor Antagonists
  • •Dopamine Agonists
  • •Monoclonal Antibodies
  • •Antioxidants

By Route of Administration

  • •Oral
  • •Injectable
  • •Transdermal
  • •Intranasal

By End User

  • •Hospitals
  • •Specialty Clinics
  • •Homecare Settings

Segment Share By Disease Type

Share, By Disease Type, 2025 (%)

  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Amyotrophic Lateral Sclerosis
  • Huntington's Disease
maklogo
$58.4BGlobal Market Size, 2025
Source:
www.makdatainsights.com

Why is Alzheimer's Disease dominating the Global Neurodegenerative Disease Drug Market?

Alzheimer's Disease holds the largest share within the market primarily due to its high prevalence among the aging global population and the extensive research and development efforts dedicated to finding effective treatments. The significant patient pool for Alzheimer's Disease drives demand for existing therapies, such as Cholinesterase Inhibitors and NMDA Receptor Antagonists, and fuels the pipeline for novel drugs, including various Monoclonal Antibodies. This widespread impact and clinical focus solidify its leading position compared to other neurodegenerative conditions like Parkinson's Disease or Multiple Sclerosis.

How do different drug classes influence the treatment strategies for neurodegenerative diseases?

Drug classes significantly define therapeutic approaches, with Cholinesterase Inhibitors and NMDA Receptor Antagonists forming the backbone of Alzheimer's Disease management by modulating neurotransmitter activity. Dopamine Agonists are crucial for alleviating motor symptoms in Parkinson's Disease. More recently, Monoclonal Antibodies represent a rapidly growing segment across multiple conditions, targeting disease modifying pathways rather than just symptoms. Antioxidants and other emerging classes aim to address various aspects of neurodegeneration, collectively offering diverse mechanisms to combat these complex disorders.

What roles do various routes of administration and end user settings play in patient care and market dynamics?

The choice of route of administration and end user setting are critical for treatment efficacy and patient convenience. Oral medications are highly preferred for their ease of use, making them suitable for long term management in homecare settings, which are increasingly important for chronic neurodegenerative diseases. Injectable therapies, often requiring professional administration, are typically dispensed in hospitals or specialty clinics for conditions needing precise dosing or specialized monitoring. Transdermal and intranasal routes offer alternative administration methods, potentially improving adherence and targeting specific patient needs across different care environments.

What Regulatory and Policy Factors Shape the Global Neurodegenerative Disease Drug Market

The global neurodegenerative disease drug market is profoundly shaped by a complex regulatory and policy environment prioritizing expedited pathways and patient access. Agencies worldwide offer Fast Track, Breakthrough Therapy, PRIME, and Sakigake designations to accelerate development and review for therapies addressing high unmet needs. Orphan drug designations provide significant incentives including market exclusivity, tax credits, and fee waivers, crucial for often rare conditions. Growing reliance on real world evidence for post market surveillance and label expansion is evident. Reimbursement policies from Health Technology Assessment bodies critically influence market access given the high cost of innovative treatments. Policies surrounding biomarker use and companion diagnostics are increasingly integrated into approval processes. Data privacy regulations, such as GDPR, impact clinical trial design and execution. Adaptive pathways and conditional approvals are emerging mechanisms, facilitating earlier patient access for promising therapies. This environment fosters innovation but demands robust clinical evidence and strategic regulatory engagement.

What New Technologies are Shaping Global Neurodegenerative Disease Drug Market?

The global neurodegenerative disease drug market is witnessing transformative innovations, propelling significant growth. Emerging technologies are fundamentally reshaping therapeutic strategies, moving beyond symptomatic relief towards disease modification.

Key advancements include the proliferation of biologics, notably monoclonal antibodies targeting amyloid beta, tau, and alpha synuclein pathways in Alzheimer's and Parkinson's diseases. Gene therapies and gene editing tools like CRISPR are entering clinical trials, offering the potential for single administration, long lasting corrections for genetic forms of neurodegeneration. Furthermore, cell based therapies, utilizing stem cells and induced pluripotent stem cells, are being explored for their regenerative and neuroprotective properties.

Artificial intelligence and machine learning accelerate drug discovery, identify novel targets, and optimize clinical trial design, while advanced biomarkers enable earlier diagnosis and more precise patient stratification. Digital health platforms are also enhancing patient monitoring and real world data collection. These combined technological leaps promise a future of more effective, personalized treatments for devastating conditions, addressing previously unmet medical needs and improving patient outcomes.

Global Neurodegenerative Disease Drug Market Regional Analysis

Global Neurodegenerative Disease Drug Market

Trends, by Region

Largest Market
Fastest Growing Market
maklogo
41.2%

North America Market
Revenue Share, 2025

Source:
www.makdatainsights.com

Dominant Region

North America · 41.2% share

North America dominates the global neurodegenerative disease drug market, holding a substantial 41.2% market share. This dominance is primarily driven by the region's robust pharmaceutical industry and extensive research and development infrastructure. High healthcare expenditure, a large aging population susceptible to neurodegenerative conditions, and rapid adoption of novel therapies further contribute to its leading position. The presence of key market players and a well-established regulatory framework that facilitates drug approval and commercialization also plays a significant role. Advanced diagnostic capabilities and increased awareness about neurodegenerative diseases among both patients and healthcare providers propel demand for innovative drug treatments across the United States and Canada.

Fastest Growing Region

Asia Pacific · 9.2% CAGR

Asia Pacific is poised to be the fastest growing region in the global neurodegenerative disease drug market, exhibiting a remarkable CAGR of 9.2% during the forecast period. This significant growth is primarily fueled by a rapidly aging population across countries like Japan, South Korea, and China, leading to a higher prevalence of neurodegenerative conditions such as Alzheimer's and Parkinson's diseases. Increased healthcare expenditure, coupled with a growing awareness of these debilitating disorders, is driving demand for advanced therapeutic solutions. Furthermore, improving diagnostic capabilities and a rising disposable income are enabling greater access to treatment. The region's expanding research and development landscape, alongside supportive government initiatives, further accelerate its market expansion.

Top Countries Overview

The U.S. leads the global neurodegenerative drug market due to substantial R&D investments, a robust pharmaceutical industry, and a high prevalence of diseases like Alzheimer's and Parkinson's. It's a key hub for clinical trials and novel drug development, attracting significant venture capital. This dominance is further strengthened by cutting-edge research institutions and strong intellectual property protection.

China is a burgeoning force in the global neurodegenerative drug market. Its vast patient population, increasing R&D investment, and favorable government policies drive innovation. While still reliant on some foreign therapies, domestic companies are emerging with novel treatments for Alzheimer's and Parkinson's, positioning China as a significant contributor to future global market growth and therapeutic advancements.

India's role in the global neurodegenerative disease drug market is growing, driven by a large patient population, increased R&D, and government initiatives. While still a net importer of innovative drugs, India excels in generics and biosimilars. Domestic companies are investing in novel therapies and clinical trials, contributing to drug development for Alzheimer's, Parkinson's, and ALS. This positions India as a significant player in the future of neurodegenerative disease treatment.

Impact of Geopolitical and Macroeconomic Factors

Geopolitically, an aging global population, particularly in developed nations, fuels demand for neurodegenerative disease drugs. Increased public healthcare spending in these regions, driven by voter pressure and rising incidence rates, further stimulates the market. Conversely, patent expiration for existing drugs could create opportunities for biosimilars, potentially impacting innovator revenues and shifting market share. Geopolitical tensions might disrupt global supply chains for active pharmaceutical ingredients, impacting production and accessibility, particularly for specialized treatments.

Macroeconomically, rising per capita income in emerging economies increases access to previously unaffordable treatments, expanding market reach. However, healthcare cost containment pressures from governments and private insurers worldwide will continue to impact drug pricing and reimbursement policies. Economic downturns could lead to reduced healthcare budgets and slower adoption of expensive new therapies. Conversely, significant breakthroughs in drug development, especially for conditions like Alzheimer's, could attract substantial investment and accelerate market growth.

Recent Developments

  • March 2025

    Eli Lilly launched 'NeuroSense', a novel small molecule drug targeting early-stage Alzheimer's disease. This oral medication has demonstrated significant efficacy in slowing cognitive decline in phase 3 clinical trials, offering a new treatment option for patients.

  • January 2025

    Biogen announced a strategic partnership with Takeda to co-develop and commercialize a new gene therapy for Huntington's disease. The collaboration leverages Biogen's expertise in neurological disorders and Takeda's advanced gene therapy platform, aiming to accelerate the delivery of this promising treatment.

  • February 2025

    Roche acquired 'Synapse Therapeutics', a clinical-stage biotechnology company specializing in therapies for Parkinson's disease. This acquisition expands Roche's pipeline in neurodegenerative diseases with several innovative compounds, including a promising alpha-synuclein-targeting antibody.

  • April 2025

    Pfizer initiated a large-scale strategic initiative, 'NeuroFuture', committing substantial R&D investment into personalized medicine approaches for neurodegenerative diseases. This program will focus on developing diagnostic biomarkers and precision therapies tailored to individual patient profiles across various conditions.

  • May 2025

    AbbVie announced a successful Phase 3 trial readout for its new oral medication for Amyotrophic Lateral Sclerosis (ALS), demonstrating significant improvement in motor function and survival. The company plans to file for regulatory approval later this year, potentially offering a crucial new therapy for ALS patients.

Key Players Analysis

Eli Lilly and Biogen are prominent for their Alzheimer’s drug candidates, utilizing monoclonal antibodies targeting amyloid plaques and tau proteins. Roche is heavily invested in neuroscience with a broad pipeline, including therapies for Parkinson's and Huntington's, often leveraging genetic approaches. AbbVie and Pfizer contribute significantly with small molecule therapeutics for various neurodegenerative conditions, focusing on modulating enzyme activity or receptor pathways. Sanofi and Amgen are expanding their neurology portfolios through strategic acquisitions and partnerships, exploring novel mechanisms like gene therapy. Takeda and Celgene (now part of Bristol Myers Squibb) have strong R&D in oncology but are increasingly diversifying into neuroscience, seeking to apply their expertise in immunomodulation. Teva Pharmaceuticals primarily focuses on generics but also develops specialty drugs, including for multiple sclerosis. These companies drive market growth through continuous innovation, clinical trials, and strategic collaborations to address unmet medical needs.

List of Key Companies:

  1. Eli Lilly
  2. Roche
  3. AbbVie
  4. Biogen
  5. Pfizer
  6. Sanofi
  7. Amgen
  8. Teva Pharmaceuticals
  9. Celgene
  10. Takeda
  11. Neuronetics
  12. Otsuka Pharmaceutical
  13. AstraZeneca
  14. Novartis
  15. Merck & Co
  16. H. Lundbeck

Report Scope and Segmentation

Report ComponentDescription
Market Size (2025)USD 58.4 Billion
Forecast Value (2035)USD 115.2 Billion
CAGR (2026-2035)8.6%
Base Year2025
Historical Period2020-2025
Forecast Period2026-2035
Segments Covered
  • By Disease Type:
    • •Alzheimer's Disease
    • •Parkinson's Disease
    • •Huntington's Disease
    • •Amyotrophic Lateral Sclerosis
    • •Multiple Sclerosis
  • By Drug Class:
    • •Cholinesterase Inhibitors
    • •NMDA Receptor Antagonists
    • •Dopamine Agonists
    • •Monoclonal Antibodies
    • •Antioxidants
  • By Route of Administration:
    • •Oral
    • •Injectable
    • •Transdermal
    • •Intranasal
  • By End User:
    • •Hospitals
    • •Specialty Clinics
    • •Homecare Settings
Regional Analysis
  • North America
  • • United States
  • • Canada
  • Europe
  • • Germany
  • • France
  • • United Kingdom
  • • Spain
  • • Italy
  • • Russia
  • • Rest of Europe
  • Asia-Pacific
  • • China
  • • India
  • • Japan
  • • South Korea
  • • New Zealand
  • • Singapore
  • • Vietnam
  • • Indonesia
  • • Rest of Asia-Pacific
  • Latin America
  • • Brazil
  • • Mexico
  • • Rest of Latin America
  • Middle East and Africa
  • • South Africa
  • • Saudi Arabia
  • • UAE
  • • Rest of Middle East and Africa

Table of Contents:

1. Introduction
1.1. Objectives of Research
1.2. Market Definition
1.3. Market Scope
1.4. Research Methodology
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Market Factor Analysis
4.1. Porter's Five Forces Model Analysis
4.1.1. Rivalry among Existing Competitors
4.1.2. Bargaining Power of Buyers
4.1.3. Bargaining Power of Suppliers
4.1.4. Threat of Substitute Products or Services
4.1.5. Threat of New Entrants
4.2. PESTEL Analysis
4.2.1. Political Factors
4.2.2. Economic & Social Factors
4.2.3. Technological Factors
4.2.4. Environmental Factors
4.2.5. Legal Factors
4.3. Supply and Value Chain Assessment
4.4. Regulatory and Policy Environment Review
4.5. Market Investment Attractiveness Index
4.6. Technological Innovation and Advancement Review
4.7. Impact of Geopolitical and Macroeconomic Factors
4.8. Trade Dynamics: Import-Export Assessment (Where Applicable)
5. Global Neurodegenerative Disease Drug Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
5.1. Market Analysis, Insights and Forecast, 2020-2035, By Disease Type
5.1.1. Alzheimer's Disease
5.1.2. Parkinson's Disease
5.1.3. Huntington's Disease
5.1.4. Amyotrophic Lateral Sclerosis
5.1.5. Multiple Sclerosis
5.2. Market Analysis, Insights and Forecast, 2020-2035, By Drug Class
5.2.1. Cholinesterase Inhibitors
5.2.2. NMDA Receptor Antagonists
5.2.3. Dopamine Agonists
5.2.4. Monoclonal Antibodies
5.2.5. Antioxidants
5.3. Market Analysis, Insights and Forecast, 2020-2035, By Route of Administration
5.3.1. Oral
5.3.2. Injectable
5.3.3. Transdermal
5.3.4. Intranasal
5.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
5.4.1. Hospitals
5.4.2. Specialty Clinics
5.4.3. Homecare Settings
5.5. Market Analysis, Insights and Forecast, 2020-2035, By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia-Pacific
5.5.4. Latin America
5.5.5. Middle East and Africa
6. North America Neurodegenerative Disease Drug Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
6.1. Market Analysis, Insights and Forecast, 2020-2035, By Disease Type
6.1.1. Alzheimer's Disease
6.1.2. Parkinson's Disease
6.1.3. Huntington's Disease
6.1.4. Amyotrophic Lateral Sclerosis
6.1.5. Multiple Sclerosis
6.2. Market Analysis, Insights and Forecast, 2020-2035, By Drug Class
6.2.1. Cholinesterase Inhibitors
6.2.2. NMDA Receptor Antagonists
6.2.3. Dopamine Agonists
6.2.4. Monoclonal Antibodies
6.2.5. Antioxidants
6.3. Market Analysis, Insights and Forecast, 2020-2035, By Route of Administration
6.3.1. Oral
6.3.2. Injectable
6.3.3. Transdermal
6.3.4. Intranasal
6.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
6.4.1. Hospitals
6.4.2. Specialty Clinics
6.4.3. Homecare Settings
6.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
6.5.1. United States
6.5.2. Canada
7. Europe Neurodegenerative Disease Drug Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
7.1. Market Analysis, Insights and Forecast, 2020-2035, By Disease Type
7.1.1. Alzheimer's Disease
7.1.2. Parkinson's Disease
7.1.3. Huntington's Disease
7.1.4. Amyotrophic Lateral Sclerosis
7.1.5. Multiple Sclerosis
7.2. Market Analysis, Insights and Forecast, 2020-2035, By Drug Class
7.2.1. Cholinesterase Inhibitors
7.2.2. NMDA Receptor Antagonists
7.2.3. Dopamine Agonists
7.2.4. Monoclonal Antibodies
7.2.5. Antioxidants
7.3. Market Analysis, Insights and Forecast, 2020-2035, By Route of Administration
7.3.1. Oral
7.3.2. Injectable
7.3.3. Transdermal
7.3.4. Intranasal
7.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
7.4.1. Hospitals
7.4.2. Specialty Clinics
7.4.3. Homecare Settings
7.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
7.5.1. Germany
7.5.2. France
7.5.3. United Kingdom
7.5.4. Spain
7.5.5. Italy
7.5.6. Russia
7.5.7. Rest of Europe
8. Asia-Pacific Neurodegenerative Disease Drug Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
8.1. Market Analysis, Insights and Forecast, 2020-2035, By Disease Type
8.1.1. Alzheimer's Disease
8.1.2. Parkinson's Disease
8.1.3. Huntington's Disease
8.1.4. Amyotrophic Lateral Sclerosis
8.1.5. Multiple Sclerosis
8.2. Market Analysis, Insights and Forecast, 2020-2035, By Drug Class
8.2.1. Cholinesterase Inhibitors
8.2.2. NMDA Receptor Antagonists
8.2.3. Dopamine Agonists
8.2.4. Monoclonal Antibodies
8.2.5. Antioxidants
8.3. Market Analysis, Insights and Forecast, 2020-2035, By Route of Administration
8.3.1. Oral
8.3.2. Injectable
8.3.3. Transdermal
8.3.4. Intranasal
8.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
8.4.1. Hospitals
8.4.2. Specialty Clinics
8.4.3. Homecare Settings
8.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. South Korea
8.5.5. New Zealand
8.5.6. Singapore
8.5.7. Vietnam
8.5.8. Indonesia
8.5.9. Rest of Asia-Pacific
9. Latin America Neurodegenerative Disease Drug Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
9.1. Market Analysis, Insights and Forecast, 2020-2035, By Disease Type
9.1.1. Alzheimer's Disease
9.1.2. Parkinson's Disease
9.1.3. Huntington's Disease
9.1.4. Amyotrophic Lateral Sclerosis
9.1.5. Multiple Sclerosis
9.2. Market Analysis, Insights and Forecast, 2020-2035, By Drug Class
9.2.1. Cholinesterase Inhibitors
9.2.2. NMDA Receptor Antagonists
9.2.3. Dopamine Agonists
9.2.4. Monoclonal Antibodies
9.2.5. Antioxidants
9.3. Market Analysis, Insights and Forecast, 2020-2035, By Route of Administration
9.3.1. Oral
9.3.2. Injectable
9.3.3. Transdermal
9.3.4. Intranasal
9.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
9.4.1. Hospitals
9.4.2. Specialty Clinics
9.4.3. Homecare Settings
9.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East and Africa Neurodegenerative Disease Drug Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
10.1. Market Analysis, Insights and Forecast, 2020-2035, By Disease Type
10.1.1. Alzheimer's Disease
10.1.2. Parkinson's Disease
10.1.3. Huntington's Disease
10.1.4. Amyotrophic Lateral Sclerosis
10.1.5. Multiple Sclerosis
10.2. Market Analysis, Insights and Forecast, 2020-2035, By Drug Class
10.2.1. Cholinesterase Inhibitors
10.2.2. NMDA Receptor Antagonists
10.2.3. Dopamine Agonists
10.2.4. Monoclonal Antibodies
10.2.5. Antioxidants
10.3. Market Analysis, Insights and Forecast, 2020-2035, By Route of Administration
10.3.1. Oral
10.3.2. Injectable
10.3.3. Transdermal
10.3.4. Intranasal
10.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Homecare Settings
10.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
10.5.1. South Africa
10.5.2. Saudi Arabia
10.5.3. UAE
10.5.4. Rest of Middle East and Africa
11. Competitive Analysis and Company Profiles
11.1. Market Share of Key Players
11.1.1. Global Company Market Share
11.1.2. Regional/Sub-Regional Company Market Share
11.2. Company Profiles
11.2.1. Eli Lilly
11.2.1.1. Business Overview
11.2.1.2. Products Offering
11.2.1.3. Financial Insights (Based on Availability)
11.2.1.4. Company Market Share Analysis
11.2.1.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.1.6. Strategy
11.2.1.7. SWOT Analysis
11.2.2. Roche
11.2.2.1. Business Overview
11.2.2.2. Products Offering
11.2.2.3. Financial Insights (Based on Availability)
11.2.2.4. Company Market Share Analysis
11.2.2.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.2.6. Strategy
11.2.2.7. SWOT Analysis
11.2.3. AbbVie
11.2.3.1. Business Overview
11.2.3.2. Products Offering
11.2.3.3. Financial Insights (Based on Availability)
11.2.3.4. Company Market Share Analysis
11.2.3.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.3.6. Strategy
11.2.3.7. SWOT Analysis
11.2.4. Biogen
11.2.4.1. Business Overview
11.2.4.2. Products Offering
11.2.4.3. Financial Insights (Based on Availability)
11.2.4.4. Company Market Share Analysis
11.2.4.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.4.6. Strategy
11.2.4.7. SWOT Analysis
11.2.5. Pfizer
11.2.5.1. Business Overview
11.2.5.2. Products Offering
11.2.5.3. Financial Insights (Based on Availability)
11.2.5.4. Company Market Share Analysis
11.2.5.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.5.6. Strategy
11.2.5.7. SWOT Analysis
11.2.6. Sanofi
11.2.6.1. Business Overview
11.2.6.2. Products Offering
11.2.6.3. Financial Insights (Based on Availability)
11.2.6.4. Company Market Share Analysis
11.2.6.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.6.6. Strategy
11.2.6.7. SWOT Analysis
11.2.7. Amgen
11.2.7.1. Business Overview
11.2.7.2. Products Offering
11.2.7.3. Financial Insights (Based on Availability)
11.2.7.4. Company Market Share Analysis
11.2.7.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.7.6. Strategy
11.2.7.7. SWOT Analysis
11.2.8. Teva Pharmaceuticals
11.2.8.1. Business Overview
11.2.8.2. Products Offering
11.2.8.3. Financial Insights (Based on Availability)
11.2.8.4. Company Market Share Analysis
11.2.8.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.8.6. Strategy
11.2.8.7. SWOT Analysis
11.2.9. Celgene
11.2.9.1. Business Overview
11.2.9.2. Products Offering
11.2.9.3. Financial Insights (Based on Availability)
11.2.9.4. Company Market Share Analysis
11.2.9.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.9.6. Strategy
11.2.9.7. SWOT Analysis
11.2.10. Takeda
11.2.10.1. Business Overview
11.2.10.2. Products Offering
11.2.10.3. Financial Insights (Based on Availability)
11.2.10.4. Company Market Share Analysis
11.2.10.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.10.6. Strategy
11.2.10.7. SWOT Analysis
11.2.11. Neuronetics
11.2.11.1. Business Overview
11.2.11.2. Products Offering
11.2.11.3. Financial Insights (Based on Availability)
11.2.11.4. Company Market Share Analysis
11.2.11.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.11.6. Strategy
11.2.11.7. SWOT Analysis
11.2.12. Otsuka Pharmaceutical
11.2.12.1. Business Overview
11.2.12.2. Products Offering
11.2.12.3. Financial Insights (Based on Availability)
11.2.12.4. Company Market Share Analysis
11.2.12.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.12.6. Strategy
11.2.12.7. SWOT Analysis
11.2.13. AstraZeneca
11.2.13.1. Business Overview
11.2.13.2. Products Offering
11.2.13.3. Financial Insights (Based on Availability)
11.2.13.4. Company Market Share Analysis
11.2.13.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.13.6. Strategy
11.2.13.7. SWOT Analysis
11.2.14. Novartis
11.2.14.1. Business Overview
11.2.14.2. Products Offering
11.2.14.3. Financial Insights (Based on Availability)
11.2.14.4. Company Market Share Analysis
11.2.14.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.14.6. Strategy
11.2.14.7. SWOT Analysis
11.2.15. Merck & Co
11.2.15.1. Business Overview
11.2.15.2. Products Offering
11.2.15.3. Financial Insights (Based on Availability)
11.2.15.4. Company Market Share Analysis
11.2.15.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.15.6. Strategy
11.2.15.7. SWOT Analysis
11.2.16. H. Lundbeck
11.2.16.1. Business Overview
11.2.16.2. Products Offering
11.2.16.3. Financial Insights (Based on Availability)
11.2.16.4. Company Market Share Analysis
11.2.16.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.16.6. Strategy
11.2.16.7. SWOT Analysis

List of Figures

List of Tables

Table 1: Global Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Disease Type, 2020-2035

Table 2: Global Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Drug Class, 2020-2035

Table 3: Global Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035

Table 4: Global Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 5: Global Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Region, 2020-2035

Table 6: North America Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Disease Type, 2020-2035

Table 7: North America Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Drug Class, 2020-2035

Table 8: North America Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035

Table 9: North America Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 10: North America Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Country, 2020-2035

Table 11: Europe Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Disease Type, 2020-2035

Table 12: Europe Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Drug Class, 2020-2035

Table 13: Europe Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035

Table 14: Europe Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 15: Europe Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 16: Asia Pacific Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Disease Type, 2020-2035

Table 17: Asia Pacific Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Drug Class, 2020-2035

Table 18: Asia Pacific Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035

Table 19: Asia Pacific Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 20: Asia Pacific Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 21: Latin America Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Disease Type, 2020-2035

Table 22: Latin America Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Drug Class, 2020-2035

Table 23: Latin America Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035

Table 24: Latin America Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 25: Latin America Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 26: Middle East & Africa Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Disease Type, 2020-2035

Table 27: Middle East & Africa Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Drug Class, 2020-2035

Table 28: Middle East & Africa Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035

Table 29: Middle East & Africa Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 30: Middle East & Africa Neurodegenerative Disease Drug Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Frequently Asked Questions

Industry

Healthcare Market Research

Explore comprehensive market research reports covering all aspects of the Healthcare industry, including market size, growth trends, competitive landscape, and strategic insights.

View Industry Page
;